PASG - Passage Bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Philadelphia,
United States
Type: Equity
PASG price evolution
PASG
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $24.77 | $36.77 | $21.71 | |
| Short term investments | $67 | $67.75 | $92.58 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $87.22 | $95 | $108.29 | $117.96 |
| Long term investments | ||||
| Property, plant & equipment | $24.07 | $29.88 | $31.58 | $32.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $30.39 | $32.24 | $32.59 | |
| Total investments | $67 | $67.75 | $92.58 | |
| Total assets | $111.75 | $125.39 | $140.53 | $150.54 |
| Current liabilities | ||||
| Accounts payable | $1.49 | $0.62 | $1.69 | $1.3 |
| Deferred revenue | ||||
| Short long term debt | $3.7 | $3.67 | $3.37 | |
| Total current liabilities | $16.95 | $12.38 | $12.84 | $16.34 |
| Long term debt | $22.45 | $22.81 | $22.92 | |
| Total noncurrent liabilities | $22.45 | $22.81 | $22.92 | |
| Total debt | $26.15 | $26.48 | $26.29 | |
| Total liabilities | $39.04 | $34.84 | $35.65 | $39.26 |
| Shareholders' equity | ||||
| Retained earnings | -$646.51 | -$627.17 | -$611.18 | -$594.47 |
| Other shareholder equity | $0.03 | -$0.07 | -$0.07 | -$0.04 |
| Total shareholder equity | $90.56 | $104.88 | $111.28 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $21.71 | $34.6 | $128.97 | $135 |
| Short term investments | $92.58 | $155.01 | $186.81 | $169.81 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $117.96 | $197.04 | $325.07 | $317.18 |
| Long term investments | ||||
| Property, plant & equipment | $32.15 | $42.24 | $23.81 | $2.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $32.59 | $46.51 | $30.01 | $10.82 |
| Total investments | $92.58 | $155.01 | $186.81 | $169.81 |
| Total assets | $150.54 | $243.55 | $355.08 | $328.01 |
| Current liabilities | ||||
| Accounts payable | $1.3 | $4.07 | $9.45 | $5.26 |
| Deferred revenue | ||||
| Short long term debt | $3.37 | $3.27 | ||
| Total current liabilities | $16.34 | $18.35 | $29.5 | $21.18 |
| Long term debt | $22.92 | $23.83 | ||
| Total noncurrent liabilities | $22.92 | $23.83 | $6.92 | $2.12 |
| Total debt | $26.29 | $27.11 | ||
| Total liabilities | $39.26 | $42.18 | $36.42 | $23.29 |
| Shareholders' equity | ||||
| Retained earnings | -$594.47 | -$492.41 | -$356.28 | -$170.9 |
| Other shareholder equity | -$0.04 | -$0.97 | -$0.41 | -$0.01 |
| Total shareholder equity | $111.28 | $201.37 | $318.66 | $304.71 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $10.43 | $11.54 | $12.16 | |
| Selling, general & administrative | $6.51 | $6.51 | $6.29 | |
| Total operating expenses | $15.91 | $15.99 | $16.71 | $16.76 |
| Operating income | -$15.99 | -$16.71 | -$16.76 | |
| Income from continuing operations | ||||
| EBIT | -$15.99 | -$16.71 | -$16.76 | |
| Income tax expense | ||||
| Interest expense | $1.1 | |||
| Net income | ||||
| Net income | -$19.34 | -$15.99 | -$16.71 | -$16.76 |
| Income (for common shares) | -$15.99 | -$16.71 | -$16.76 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $61.42 | $86.05 | $117.67 | $81.79 |
| Selling, general & administrative | $41.58 | $49.34 | $60.06 | $30.11 |
| Total operating expenses | $102.06 | $138.39 | $185.73 | $112.9 |
| Operating income | -$102.06 | -$138.39 | -$185.73 | -$112.9 |
| Income from continuing operations | ||||
| EBIT | -$102.06 | -$136.13 | -$185.39 | -$112.23 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$102.06 | -$136.13 | -$185.39 | -$112.23 |
| Income (for common shares) | -$102.06 | -$136.13 | -$185.39 | -$112.23 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$15.99 | -$16.71 | -$16.76 | |
| Operating activities | ||||
| Depreciation | $0.8 | $0.81 | $0.81 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.58 | $1.59 | $1.57 | |
| Total cash flows from operations | -$13.14 | -$18.93 | -$19.52 | |
| Investing activities | ||||
| Capital expenditures | -$0.01 | |||
| Investments | $1.05 | $25.25 | $7.61 | |
| Total cash flows from investing | $41.27 | $1.05 | $25.25 | $7.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.09 | $8.74 | $0.05 | |
| Net borrowings | ||||
| Total cash flows from financing | $8.83 | $0.09 | $8.74 | $0.05 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $10.58 | -$12 | $15.06 | -$11.87 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$102.06 | -$136.13 | -$185.39 | -$112.23 |
| Operating activities | ||||
| Depreciation | $3.72 | $3.68 | $1.54 | $0.8 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.92 | $18.95 | $32.69 | $14.58 |
| Total cash flows from operations | -$78.26 | -$118.21 | -$126.88 | -$80.52 |
| Investing activities | ||||
| Capital expenditures | -$0.15 | -$5.27 | -$25.64 | -$1.15 |
| Investments | $65.38 | $30.47 | -$20.17 | -$170.46 |
| Total cash flows from investing | $65.24 | $25.2 | -$45.81 | -$172.11 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.14 | $0.43 | $166.99 | $228.75 |
| Net borrowings | -$1.79 | |||
| Total cash flows from financing | $0.14 | -$1.35 | $166.66 | $228.75 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$12.89 | -$94.36 | -$6.04 | -$23.87 |
News
Fundamentals
| Market cap | $605.01M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 61.77M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$68.80M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -8.79 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.11 |
|---|---|
| ROA | -52.10% |
| ROE | N/A |
| Debt/Equity | 0.35 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.15 |
| Quick ratio | N/A |